Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.38 |
| ▸ | PLK1 | P53350 | 3/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769392 | 0.91 | LRRK2 (0.32) | LRRK2PLK1ALKNUAK1 | |
| SCHEMBL15770073 | 0.90 | LCK (0.35) | LRRK2PLK1ALK | |
| SCHEMBL15769944 | 0.89 | LRRK2 (0.31) | LRRK2PLK1 | |
| SCHEMBL15769708 | 0.89 | ALK (0.35) | LRRK2ALK | |
| SCHEMBL15769752 | 0.88 | LRRK2 (0.41) | LRRK2PLK1 | |
| SCHEMBL15769905 | 0.87 | CDK1 (0.40) | LRRK2PLK1NUAK1 | |
| SCHEMBL15770221 | 0.82 | PLK1 (0.34) | LRRK2PLK1ALK | |
| SCHEMBL15769445 | 0.82 | JAK3 (0.38) | PLK1 | |
| SCHEMBL15769776 | 0.82 | CSNK2A2 (0.34) | PLK1 | |
| SCHEMBL15769434 | 0.81 | LRRK2 (0.42) | LRRK2PLK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | claimed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | LRRK2 427/4885PLK1 143/4885ALK 1486/4885 |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | LRRK2 427/4885PLK1 143/4885ALK 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.